AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34700679
Drug: Palliative intent
RxNorm normalized name: Various pain palliation radiopharmaceuticals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative intent radiation therapy
Trial: 34700679
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment volume
Trial: 34700679
Drug: Palliative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative treatment intent
Trial: 36160134
Drug: SoC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SoC plus nitazoxanide (1,000 mg b.i.d.) and atazanavir/ritonavir (300/100 mg od)
Trial: 32326954
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive therapy for PTSD (iCT-PTSD)
Trial: 32326954
Drug: Internet-delivered stress
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered stress management therapy (iStress-PTSD)
Trial: 32115477
Drug: Nalmefene 10
RxNorm normalized name: nalmefene 100 MCG in 1 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 10 mg
Trial: 37280688
Drug: Lamotrigine (LTG)
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine (LTG) 300 mg
Trial: 34872895
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg of Ellagic Acid (EA) per day for 2 months
Trial: 34981592
Drug: Patient Centeredness
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient Centeredness Index (PCI) survey administered to patients with chronic conditions
Trial: 33704620
Drug: Doxorubicin 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 40 mg/m2 and lurbinectedin 2.0 mg/m2 on Day 1 q3wk
Trial: 33704620
Drug: Doxorubicin 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 40 mg/m2 and lurbinectedin 2.0 mg/m2 on Day 1 q3wk in sensitive disease
Trial: 33704620
Drug: Doxorubicin 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 40 mg/m2 and lurbinectedin 2.0 mg/m2 on Day 1 q3wk in resistant disease
Trial: 32852553
Drug: Education and
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education and personalized text message reminders daily to prompt directly supervised therapy (intervention group)
Trial: 33528110
Drug: Partially guided
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially guided template (test group 1, 36 implants)
Trial: 33528110
Drug: Fully guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fully guided template (test group 2, 33 implants)
Trial: 33528110
Drug: Routine implant‐supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine implant‐supported restoration treatment (control group, 30 implants)
Trial: 32862007
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (40 i.u.)
Trial: 33106606
Drug: PEG‐ELS 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐ELS 40 (40 ml/kg)
Trial: 33106606
Drug: PEG‐ELS 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐ELS 60 (60 ml/kg)
Trial: 35382059
Drug: IV dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV dexmedetomidine 1 µg/kg over 10 min
Trial: 35266219
Drug: FGE dark
RxNorm normalized name: dark leaved mugwort pollen extract
DrugBank: Artemisia ludoviciana pollen (DB10762)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FGE dark chocolate (5 g/day containing 650 mg of FGE powder)
Trial: 32016118
Drug: Intravitreal Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal Bevacizumab (IVB) plus topical dorzolamide 2% twice daily
Trial: 32016118
Drug: Intravitreal Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal Bevacizumab (IVB) alone plus topical artificial tear twice daily
Trial: 33476595
Drug: Cytoreductive surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery plus HIPEC (360 mg/m2 closed abdomen or 460 mg/m2 open abdomen)
Trial: 32841748
Drug: Epicutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epicutaneous immunotherapy (DBV712 250 μg, daily epicutaneous peanut protein)
Trial: 35257614
Drug: Linear mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linear mixed effects model with random treatment effects
Trial: 35141396
Drug: 40 Hz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 Hz transcranial alternating current stimulation (tACS) for 30 days, 1-hour daily sessions
Trial: 34481729
Drug: Inhaled allergen-specific
RxNorm normalized name: Pacific halibut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled allergen-specific IgE antibody positivity measurement
Trial: 34481729
Drug: Specific IgE
RxNorm normalized name: BSA specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific IgE antibodies to inhaled allergens
Trial: 32945537
Drug: Fenfluramine hydrochloride
RxNorm normalized name: fenfluramine hydrochloride
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine hydrochloride (FFA), administered as add-on, twice daily at an initial dose of 0.2 mg/kg/d up to 0.7 mg/kg/d
Trial: 33917677
Drug: Integrated oral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated oral healthcare intervention (dental assistance and collective health education actions in conversation circles)
Trial: 33596735
Drug: Daily tenofovir/emtricitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily tenofovir/emtricitabine (TDF-FTC)
Trial: 33444208
Drug: Gabapentin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (600 mg just before surgery and 600 mg/day for 2 days after surgery)
Trial: 33043552
Drug: Bisoprolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (5 mg daily for 2 weeks)
Trial: 33043552
Drug: Bisoprolol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (up to 10 mg daily in open-label extension)
Trial: 34387038
Drug: Tamsulosin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.2 mg orally once at night for 3 days starting on postoperative day 1 (treatment group)
Trial: 34387038
Drug: Non-treatment (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment (control group)
Trial: 32096613
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day SC elamipretide for 4 weeks
Trial: 32096613
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day SC elamipretide
Trial: 33872573
Drug: Negative Pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative Pressure Massage Treatment (NPMT)
Trial: 35338860
Drug: Oral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy and placebo
Trial: 36174096
Drug: PARADIES intervention
RxNorm normalized name: Citrus paradisi fruit oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARADIES intervention (combined cognitive behavioural therapy with case management)
Trial: 34714130
Drug: 100 g dried
RxNorm normalized name: peptone,dried
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g dried plum
Trial: 34714130
Drug: Control (0 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 g dried plum)
Trial: 36202391
Drug: Mixed tree
RxNorm normalized name: ALLERGENIC EXTRACT MIXED TREES INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed tree nuts (30 g/d for 4 weeks)
Trial: 33308469
Drug: ChAdOx1 nCoV‐19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 nCoV‐19 vaccine
Trial: 35641232
Drug: Vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine sulfate liposomal injection (VSLI) at 2.25 mg/m2
Trial: 35641232
Drug: Vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine sulfate liposomal injection (VSLI) with bendamustine and rituximab (BR)
Trial: 35641232
Drug: Vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine sulfate liposomal injection (VSLI)
Trial: 34823572
Drug: Prism adaptation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prism adaptation treatment (twice-daily for two weeks)
Trial: 34823572
Drug: Prism adaptation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prism adaptation treatment
Trial: 32753447
Drug: Cinacalcet plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet plus conventional therapy (cinacalcet strategy)
Trial: 32753447
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (standard strategy)
Trial: 36475294
Drug: liraglutide 3
RxNorm normalized name: liraglutide 3.6 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide 3 mg/day
Trial: 37431849
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors
Trial: 32991033
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors (ACEi)
Trial: 36094625
Drug: Standard Medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Medical Treatment (SMT)
Trial: 34146343
Drug: Antidepressant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant therapy (optimally effective)
Trial: 34146343
Drug: Antidepressant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant therapy (improvement-type model)
Trial: 34146343
Drug: Antidepressant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant therapy (adjusted for treatment discontinuation, remission-type model)
Trial: 34146343
Drug: Antidepressant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant therapy (adjusted for treatment discontinuation, improvement-type model)
Trial: 32297486
Drug: brexpiprazole 1
RxNorm normalized name: brexpiprazole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brexpiprazole 1 mg/day, increased to 2 mg/day by week 4, up to 4 mg/day according to CGI-I criteria
Trial: 35830641
Drug: Erythropoietin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (1000 U/kg) administered intravenously within 26 hours after birth and at 2, 3, 4, and 7 days of age
Trial: 35830641
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) administered intravenously within 26 hours after birth and at 2, 3, 4, and 7 days of age
Trial: 32077353
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy decisions under assumed ideal conditions
Trial: 32077353
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy decisions under current local resources
Trial: 34999737
Drug: Drug Recognition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Recognition Evaluator-conducted expanded field sobriety examination
Trial: 36053616
Drug: Continuous wound
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous wound infusion of local anaesthetic (bupivacaine) for the first 72 hours along with systemic opioid analgesia (catheter group)
Trial: 32243865
Drug: Landiolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol (1 μg/kg per min, IV infusion, can be increased to a maximum of 20 μg/kg per min)
Trial: 32243865
Drug: Control (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (conventional sepsis therapy)
Trial: 32074684
Drug: Mosapride group
RxNorm normalized name: mosapride
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride group (Mosapride citrate tablets 5 mg 3 times per day for 2 weeks)
Trial: 32074684
Drug: Combizym(®) group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combizym(®) group (Combizym tablets 244 mg 3 times per day for 2 weeks)
Trial: 32074684
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group (both drugs at same doses for 2 weeks)
Trial: 32807229
Drug: Integrative medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative medicine rehabilitation (IMR) with usual rehabilitation (UR)
Trial: 35769368
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase treatment
Trial: 35745123
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care for wound treatment
Trial: 32534040
Drug: Resveratrol (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (250 mg/day)
Trial: 33569986
Drug: FTD/TPI monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTD/TPI monotherapy
Trial: 32482095
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g protein post-exercise
Trial: 32482095
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g protein post-exercise
Trial: 32266765
Drug: Therapy dog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy dog interaction for 5 minutes
Trial: 32266765
Drug: Therapy dog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy dog interaction and coloring
Trial: 33380580
Drug: Hydrogen inhalation
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen inhalation (66.7% hydrogen and 33.3% oxygen, 3 L/min for 4 hours each day for 2 weeks)
Trial: 33166307
Drug: Intranasal GSK2245035
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal GSK2245035 20 ng once weekly for 8 weeks
Trial: 34491016
Drug: AbobotulinumtoxinA (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AbobotulinumtoxinA (all doses)
Trial: 34501925
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health intervention (oral health assessment, dental treatment recommendations, oral health education)
Trial: 35175218
Drug: Intranasal gel
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal gel with a bacteriophages mixture (Otofag, Micromir, Russia) twice a day for ten weeks
Trial: 35538296
Drug: Trimetazidine (TMZ)
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (TMZ) 35 mg twice daily
Trial: 32543020
Drug: Tolvaptan 30
RxNorm normalized name: tolvaptan 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan 30 mg orally daily
Trial: 32543020
Drug: Furosemide 5
RxNorm normalized name: furosemide 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 5 mg/h intravenously
Trial: 36171101
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis (IVT) before EVT
Trial: 35462369
Drug: Desidustat oral
RxNorm normalized name: Desidustat
DrugBank: Desidustat (DB16135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desidustat oral tablets (thrice a week) for 24 weeks
Trial: 35462369
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa subcutaneous injection for 24 weeks
Trial: 33067129
Drug: Fortified yogurt
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fortified yogurt with 3 g HMB, 1000 IU vitamin D, and 500 mg vitamin C
Trial: 35871650
Drug: Time-restricted eating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-restricted eating (TRE) for 3 weeks (daily food intake within 10 h)
Trial: 34700294
Drug: Naproxen (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (500 mg sodium, two capsules per day for five days)
Trial: 32274653
Drug: Peficitinib (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peficitinib (20, 60, or 200 mg)
Trial: 32274653
Drug: Peficitinib (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peficitinib (10, 30, or 100 mg) twice daily for 7 days
Trial: 35255229
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day empagliflozin (EMPA)
Trial: 35255229
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug (NOEMPA)
Trial: 34275586
Drug: Apatinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (500 mg/day) and Temozolomide (50 mg/m2/day)
Trial: 34487566
Drug: Low-energy CO2
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-energy CO2 laser treatment
Trial: 34653287
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (FCM) - two 15 mg/kg infusions 7 days apart; maximum dose, 750 mg single/1500 mg total
Trial: 35708895
Drug: Nomogram based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomogram based on cumulative anthracycline dose, ejection fractions, NT-proBNP, and diastolic dysfunction.
Trial: 32737585
Drug: Medical air
RxNorm normalized name: Medical air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical air (placebo) inhalation
Trial: 34787005
Drug: Ofatumumab 20
RxNorm normalized name: ofatumumab 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofatumumab 20 mg
Trial: 34847676
Drug: Transcutaneous tibial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous tibial nerve stimulation (TTNS) daily for 3 months
Trial: 34847676
Drug: Percutaneous tibial
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous tibial nerve stimulation (PTNS) weekly for 3 months
Trial: 34125899
Drug: Standard-dose VitD/Ca
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose VitD/Ca supplementation (400 IU/1200 mg/day) for 48 weeks
Trial: 34125899
Drug: High-dose VitD/Ca
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose VitD/Ca supplementation (400 IU/1200 mg/day plus ergocalciferol 20,000 IU/week) for 48 weeks
Trial: 34125899
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (Standard-dose and High-dose)
Trial: 33624240
Drug: Anaerobically digested
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaerobically digested swine manure at 25 g·kg‐1
Trial: 33624240
Drug: Anaerobically digested
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaerobically digested swine manure at 10 g·kg‐1
Trial: 33624240
Drug: Anaerobically digested
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaerobically digested swine manure at 0 g·kg‐1
Trial: 34859788
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg Mg as Mg citrate daily for 12 weeks
Trial: 36247849
Drug: CT-guided percutaneous
RxNorm normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-guided percutaneous radiofrequency ablation therapy
Trial: 35241351
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch adherence
Trial: 35241351
Drug: Quit day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quit day smoking status, patch adherence, duration of abstinence, and percent negative CO samples submitted
Trial: 36190380
Drug: Rosuvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (20 mg per day for 12 weeks)
Trial: 34291808
Drug: Digital Cognitive
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital Cognitive Behavioral Therapy for Insomnia (dCBT‐I)
Trial: 34291808
Drug: Face-to-face Cognitive
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face Cognitive Behavioral Therapy for Insomnia (FtF CBT‐I)
Trial: 34193328
Drug: Mindfulness-Based Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Therapy for Insomnia (MBTI)